Two Early Stage Biopharma Deals Focus on Oncology Assets…ARQL THOR…Update-1
Update-1 …12/12/19…China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early Stage Pipeline Deals Diversify...
Biotech Scoreboard-November: Gene Therapy Stocks Gain Momentum…Update-2– BOLD
Update-2 …12/3…Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid caps were green. RNAi...
Rayno BioBeat #3: Sentiment Shift Boosts Biotech and Healthcare Stocks Despite Political Undertow…Update-1 “green screen”
Update-1 11/25/19... Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We hold many winners today: ALNY,...
Healthcare Stocks Breakout and Biotech Stocks Rally Off the Bottom…Update-3 ALNY AMRN
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on 10/18 RNAi area heating up...
Nice Gains for Biotech Today Big and Small…Update-2
Update-2…One of the best days of the year for us; I will summarize later. Only laggard sector was speculative microcaps. Some of our best gains among healthcare/life science stocks: ABBV AMRN CRSP GILD ILMN TDOC UNH VCYT XBI ======= Update-1… Biotech gains Curbed by...